German ADC specialist Tubulis closed a €308 million (about $356 million) Series C, the largest private European raise focused on antibody‑drug conjugates to date. The financing positions the company to accelerate clinical development of TUB‑040 and expand into additional indications and earlier lines of therapy, with first clinical data due at an upcoming oncology meeting. Investors backed Tubulis’ in‑house platform engineering of ADC components and higher drug‑to‑antibody ratios. The round underscores renewed investor appetite for differentiated ADC technologies and funds expanded trials and manufacturing scale‑up.